Ir para o conteúdo principal

Vanda Pharmaceuticals (NASDAQ: VNDA) — Perfil da empresa, notícias e dados financeiros

Logo de Vanda Pharmaceuticals
VNDA Vanda Pharmaceuticals
Vanda Pharmaceuticals primary media
Perfil da empresa

Vanda Pharmaceuticals

Vanda Pharmaceuticals (NASDAQ:VNDA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies to address unmet medical needs. The company’s portfolio includes products in the areas of psychiatry, neurology, and dermatology, among others. Vanda is committed to improving patient outcomes through research and development of novel treatments. Key projects include treatments for conditions such as schizophrenia, non-24-hour sleep-wake disorder, and atopic dermatitis. Vanda’s objectives consist of advancing its clinical development programs, expanding its product portfolio through strategic partnerships and acquisitions, and delivering sustainable growth. The company strives to make a meaningful difference in patients' lives through its pioneering work in the healthcare sector.

Resumo

Public USParticipação acionária
2002Ano de fundação
273Funcionários
Washington, D.C., United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Vanda Pharmaceuticals

  • HETLIOZ (tasimelteon) - Treatment for Non-24-Hour Sleep-Wake Disorder (Non-24) and Smith-Magenis Syndrome-related sleep disorders.
  • Fanapt (iloperidone) - An antipsychotic medication for the treatment of schizophrenia.
  • Tradipitant - An investigational new drug potentially for the treatment of gastroparesis, atopic dermatitis, and motion sickness.
  • VLY-686 (Tradipitant) - A neurokinin-1 receptor antagonist, in development stages for various conditions including chronic pruritus and cough.
  • HETLIOZ LQ - A liquid formulation of tasimelteon designed for individuals who have difficulty swallowing capsules, targeting Non-24-Hour Sleep-Wake Disorder.

equipe executiva do Vanda Pharmaceuticals

  • Mihael H. PolymeropoulosFounder, President, CEO & Chairman of The Board
  • Kevin Patrick MoranSenior VP, CFO & Treasurer
  • Joakim WijkstromSenior VP & Chief Marketing Officer
  • Gunther BirznieksSenior Vice President of Business Development
  • Daniel Patrick McGuireSenior VP, General Counsel & Secretary
  • Scott L. HowellChief People Officer
  • Christos PolymeropoulosSenior Vice President & Medical Director

Principais indicadores financeiros

Resultados divulgados pela Vanda Pharmaceuticals, em USD.

Cap. de mercado
241,2 mi
Receita (TTM)
215,7 mi
P/L
—
LPA (diluído, TTM)
-4.6
Dividend yield
—
Margem de lucro
-127.4%
Receita e lucro anuais da Vanda Pharmaceuticals
Fim do ano fiscalReceitaResultado operacionalLucro líquido
216,1 mi-151,2 mi-220,5 mi
198,8 mi-40,7 mi-18,9 mi
192,6 mi-14 mi2,5 mi
254,4 mi6,3 mi6,3 mi